Consensus statement on the safety profile of topical calcineurin inhibitors.

a University of Bonn, Bonn , Germany; b University of Sheffi eld Medical School & Sheffi eld Children’s Hospital, Sheffi eld , UK; c University of Michigan Medical School, Ann Arbor, Mich. , USA; d University of Verona, Verona , Italy; e St. Johns Institute of Dermatology, St. Thomas’ Hospital, London , UK; f Dalhousie University, Halifax , Canada; g University of Münster, Münster , and h Dresden University of Technology, Dresden , Germany; i St George Hospital, University of New South Wales, Sydney , Australia; j NYU School of Medicine, New York, N.Y. , and k Northwestern University’s Feinberg School of Medicine, Chicago, Ill. , USA; l Hôpital Necker-Enfants Malades, Paris , France; m Hospital Santa Creu i Sant Pau, Barcelona , Spain; n Technical University Munich, Munich , Germany; o University Hospital, Geneva , Switzerland; p University of Kiel, Kiel , Germany; q University of Toronto, Toronto , Canada; r Medical University of Vienna, Vienna , Austria; s Central Hospital, University of Bordeaux, Bordeaux , France; t Aarhus University Hospital, Aarhus , Denmark